Effects of Glucose Load and Nateglinide Intervention on Endothelial Function and Oxidative Stress

Table 4

Comparison of biochemical parameters in newly diagnosed type 2 diabetes before and after treatment with nateglinide.

Group	Before taking nateglinide	After taking nateglinide	Difference in levels before and after nateglinide treatment	P values ​ ​
Number of patients (M/F)	32 (19/13)	32 (19/13)
Weight	71.35±10.47	70.81±9.52	0.54±4.13	.805
FPG	7.44±0.69	6.74±0.52	0.69±0.49	<.001*
PPG	14.16±2.53	10.11±2.09	4.05±2.43	<.001
DPG	6.72±2.28	3.36±2.07	3.36±2.34	<.001
HbA1C (%)	7.26±0.58	6.73±0.35	0.53±0.50	<.001*
GA (%)	16.43±1.03	14.39±0.64	2.04±0.81	<.001
TC	5.54±0.81	5.22±0.84	0.32±0.76	.062*
TG	2.10±1.07	1.81±0.58	0.30±0.87	.063*
LDL-C	3.17±0.71	2.84±0.60	0.33±0.55	.002
HDL-C	1.18±0.26	1.22±0.20	0.04±0.25	.252*
HOMA-IRI	3.62±2.91	2.86±2.18	0.76±1.75	.008
HOMA-β	56.69±45.04	59.86±44.71	3.17±25.03	.072
ALT	31.63±14.67	28.31±11.19	3.31±7.73	.044*
AST	28.97±10.80	26.66±8.10	2.31±4.61	.003*
CRE	66.75±13.31	68.22±12.79	1.47±6.27	.451*
UA	353.56±92.01	358.28±76.40	4.72±62.86	.869*

FPG: fasting plasma glucose; PPG: postprandial plasma glucose; DPG: diphosphoglycerate plasma glucose; HbA₁C: glycosylated haemoglobin; GA: glycated albumin; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HOMA-IRI: Homeostasis model method of assessment (HOMA) insulin resistance index; HOMA-β: HOMA β-cell function; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRE: creatinine; UA: uric acid.
*Using nonparametric analysis method.